First-In-Human Phase I Study of the OX40 Agonist MOXR0916 in Patients with Advanced Solid Tumors

OX40, a receptor transiently expressed by T cells upon antigen recognition, is associated with costimulation of effector T cells and impairment of regulatory T-cell function. This first-in-human study evaluated MOXR0916, a humanized effector-competent agonist IgG1 monoclonal anti-OX40 antibody. Elig...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Clinical cancer research Jg. 28; H. 16; S. 3452
Hauptverfasser:	Kim, Tae Won, Burris, Howard A, de Miguel Luken, Maria J, Pishvaian, Michael J, Bang, Yung-Jue, Gordon, Michael, Awada, Ahmad, Camidge, D Ross, Hodi, F Stephen, McArthur, Grant A, Miller, Wilson H, Cervantes, Andres, Chow, Laura Q, Lesokhin, Alexander M, Rutten, Annemie, Sznol, Mario, Rishipathak, Deepali, Chen, Shang-Chiung, Stefanich, Eric, Pourmohamad, Tony, Anderson, Maria, Kim, Jeong, Huseni, Mahrukh, Rhee, Ina, Siu, Lillian L
Format:	Journal Article
Sprache:	Englisch
Veröffentlicht:	United States 15.08.2022
Schlagworte:	Antibodies, Monoclonal, Humanized B7-H1 Antigen Carcinoma, Transitional Cell - drug therapy Humans Lung Neoplasms - drug therapy Neoplasms - pathology Urinary Bladder Neoplasms
ISSN:	1557-3265, 1557-3265
Online-Zugang:	Weitere Angaben
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Abstract	OX40, a receptor transiently expressed by T cells upon antigen recognition, is associated with costimulation of effector T cells and impairment of regulatory T-cell function. This first-in-human study evaluated MOXR0916, a humanized effector-competent agonist IgG1 monoclonal anti-OX40 antibody. Eligible patients with locally advanced or metastatic refractory solid tumors were treated with MOXR0916 intravenously once every 3 weeks (Q3W). A 3+3 dose-escalation stage (0.2-1,200 mg; n = 34) was followed by expansion cohorts at 300 mg (n = 138) for patients with melanoma, renal cell carcinoma, non-small cell lung carcinoma, urothelial carcinoma, and triple-negative breast cancer. MOXR0916 was well tolerated with no dose-limiting toxicities observed. An MTD was not reached. Most patients (95%) experienced at least one adverse event (AE); 56% of AEs, mostly grade 1-2, were related to MOXR0916. Most common treatment-related AEs included fatigue (17%), diarrhea (8%), myalgia (7%), nausea (6%), decreased appetite (6%), and infusion-related reaction (5%). Pharmacokinetic (PK) parameters were dose proportional between 80 and 1,200 mg and supported Q3W administration. The recommended expansion dose based on PK and OX40 receptor saturation was 300 mg Q3W. Immune activation and upregulation of PD-L1 was observed in a subset of paired tumor biopsies. One renal cell carcinoma patient experienced a confirmed partial response. Overall, 33% of patients achieved stable disease. Although objective responses were rarely observed with MOXR0916 monotherapy, the favorable safety profile and evidence of tumor immune activation in a subset of patients support further investigation in combination with complementary agents such as PD-1/PD-L1 antagonists.
AbstractList	OX40, a receptor transiently expressed by T cells upon antigen recognition, is associated with costimulation of effector T cells and impairment of regulatory T-cell function. This first-in-human study evaluated MOXR0916, a humanized effector-competent agonist IgG1 monoclonal anti-OX40 antibody.PURPOSEOX40, a receptor transiently expressed by T cells upon antigen recognition, is associated with costimulation of effector T cells and impairment of regulatory T-cell function. This first-in-human study evaluated MOXR0916, a humanized effector-competent agonist IgG1 monoclonal anti-OX40 antibody.Eligible patients with locally advanced or metastatic refractory solid tumors were treated with MOXR0916 intravenously once every 3 weeks (Q3W). A 3+3 dose-escalation stage (0.2-1,200 mg; n = 34) was followed by expansion cohorts at 300 mg (n = 138) for patients with melanoma, renal cell carcinoma, non-small cell lung carcinoma, urothelial carcinoma, and triple-negative breast cancer.PATIENTS AND METHODSEligible patients with locally advanced or metastatic refractory solid tumors were treated with MOXR0916 intravenously once every 3 weeks (Q3W). A 3+3 dose-escalation stage (0.2-1,200 mg; n = 34) was followed by expansion cohorts at 300 mg (n = 138) for patients with melanoma, renal cell carcinoma, non-small cell lung carcinoma, urothelial carcinoma, and triple-negative breast cancer.MOXR0916 was well tolerated with no dose-limiting toxicities observed. An MTD was not reached. Most patients (95%) experienced at least one adverse event (AE); 56% of AEs, mostly grade 1-2, were related to MOXR0916. Most common treatment-related AEs included fatigue (17%), diarrhea (8%), myalgia (7%), nausea (6%), decreased appetite (6%), and infusion-related reaction (5%). Pharmacokinetic (PK) parameters were dose proportional between 80 and 1,200 mg and supported Q3W administration. The recommended expansion dose based on PK and OX40 receptor saturation was 300 mg Q3W. Immune activation and upregulation of PD-L1 was observed in a subset of paired tumor biopsies. One renal cell carcinoma patient experienced a confirmed partial response. Overall, 33% of patients achieved stable disease.RESULTSMOXR0916 was well tolerated with no dose-limiting toxicities observed. An MTD was not reached. Most patients (95%) experienced at least one adverse event (AE); 56% of AEs, mostly grade 1-2, were related to MOXR0916. Most common treatment-related AEs included fatigue (17%), diarrhea (8%), myalgia (7%), nausea (6%), decreased appetite (6%), and infusion-related reaction (5%). Pharmacokinetic (PK) parameters were dose proportional between 80 and 1,200 mg and supported Q3W administration. The recommended expansion dose based on PK and OX40 receptor saturation was 300 mg Q3W. Immune activation and upregulation of PD-L1 was observed in a subset of paired tumor biopsies. One renal cell carcinoma patient experienced a confirmed partial response. Overall, 33% of patients achieved stable disease.Although objective responses were rarely observed with MOXR0916 monotherapy, the favorable safety profile and evidence of tumor immune activation in a subset of patients support further investigation in combination with complementary agents such as PD-1/PD-L1 antagonists.CONCLUSIONSAlthough objective responses were rarely observed with MOXR0916 monotherapy, the favorable safety profile and evidence of tumor immune activation in a subset of patients support further investigation in combination with complementary agents such as PD-1/PD-L1 antagonists. OX40, a receptor transiently expressed by T cells upon antigen recognition, is associated with costimulation of effector T cells and impairment of regulatory T-cell function. This first-in-human study evaluated MOXR0916, a humanized effector-competent agonist IgG1 monoclonal anti-OX40 antibody. Eligible patients with locally advanced or metastatic refractory solid tumors were treated with MOXR0916 intravenously once every 3 weeks (Q3W). A 3+3 dose-escalation stage (0.2-1,200 mg; n = 34) was followed by expansion cohorts at 300 mg (n = 138) for patients with melanoma, renal cell carcinoma, non-small cell lung carcinoma, urothelial carcinoma, and triple-negative breast cancer. MOXR0916 was well tolerated with no dose-limiting toxicities observed. An MTD was not reached. Most patients (95%) experienced at least one adverse event (AE); 56% of AEs, mostly grade 1-2, were related to MOXR0916. Most common treatment-related AEs included fatigue (17%), diarrhea (8%), myalgia (7%), nausea (6%), decreased appetite (6%), and infusion-related reaction (5%). Pharmacokinetic (PK) parameters were dose proportional between 80 and 1,200 mg and supported Q3W administration. The recommended expansion dose based on PK and OX40 receptor saturation was 300 mg Q3W. Immune activation and upregulation of PD-L1 was observed in a subset of paired tumor biopsies. One renal cell carcinoma patient experienced a confirmed partial response. Overall, 33% of patients achieved stable disease. Although objective responses were rarely observed with MOXR0916 monotherapy, the favorable safety profile and evidence of tumor immune activation in a subset of patients support further investigation in combination with complementary agents such as PD-1/PD-L1 antagonists.
Author	Rhee, Ina Stefanich, Eric Miller, Wilson H McArthur, Grant A Pishvaian, Michael J Chen, Shang-Chiung Kim, Jeong Awada, Ahmad Siu, Lillian L de Miguel Luken, Maria J Anderson, Maria Camidge, D Ross Rutten, Annemie Burris, Howard A Bang, Yung-Jue Huseni, Mahrukh Pourmohamad, Tony Rishipathak, Deepali Cervantes, Andres Gordon, Michael Sznol, Mario Chow, Laura Q Hodi, F Stephen Lesokhin, Alexander M Kim, Tae Won
Author_xml	– sequence: 1 givenname: Tae Won orcidid: 0000-0001-9522-1997 surname: Kim fullname: Kim, Tae Won organization: Asan Medical Center, University of Ulsan, Seoul, Korea – sequence: 2 givenname: Howard A surname: Burris fullname: Burris, Howard A organization: Sarah Cannon Research Institute, Nashville, Tennessee – sequence: 3 givenname: Maria J orcidid: 0000-0002-9366-8602 surname: de Miguel Luken fullname: de Miguel Luken, Maria J organization: START-CIOCC, Hosp. HM Sanchinarro, Madrid, Spain – sequence: 4 givenname: Michael J orcidid: 0000-0002-1165-9041 surname: Pishvaian fullname: Pishvaian, Michael J organization: Johns Hopkins University School of Medicine, Washington, DC – sequence: 5 givenname: Yung-Jue orcidid: 0000-0001-6000-4597 surname: Bang fullname: Bang, Yung-Jue organization: Seoul National University College of Medicine, Seoul, Korea – sequence: 6 givenname: Michael orcidid: 0000-0002-7679-9504 surname: Gordon fullname: Gordon, Michael organization: HonorHealth Research Institute, Scottsdale, Arizona – sequence: 7 givenname: Ahmad orcidid: 0000-0001-7412-9163 surname: Awada fullname: Awada, Ahmad organization: Jules Bordet Institute, Brussels, Belgium – sequence: 8 givenname: D Ross surname: Camidge fullname: Camidge, D Ross organization: University of Colorado Anschutz Medical Campus, Aurora, Colorado – sequence: 9 givenname: F Stephen surname: Hodi fullname: Hodi, F Stephen organization: Dana-Farber Cancer Institute, Boston, Massachusetts – sequence: 10 givenname: Grant A orcidid: 0000-0001-8908-6071 surname: McArthur fullname: McArthur, Grant A organization: Sir Peter MacCallum Department of Oncology, University of Melbourne, Victoria, Australia – sequence: 11 givenname: Wilson H surname: Miller fullname: Miller, Wilson H organization: Jewish General Hospital and Segal Cancer Centre, McGill University, Montréal, Canada – sequence: 12 givenname: Andres orcidid: 0000-0003-3806-3691 surname: Cervantes fullname: Cervantes, Andres organization: Biomedical Research Institute INCLIVA, University of Valencia, Valencia Spain – sequence: 13 givenname: Laura Q orcidid: 0000-0002-7237-017X surname: Chow fullname: Chow, Laura Q organization: University of Washington, Seattle, Washington – sequence: 14 givenname: Alexander M orcidid: 0000-0001-9321-702X surname: Lesokhin fullname: Lesokhin, Alexander M organization: Weill Cornell Medical College, New York, New York – sequence: 15 givenname: Annemie surname: Rutten fullname: Rutten, Annemie organization: GasthuisZusters Antwerpen Sint-Augustinus, Antwerp, Belgium – sequence: 16 givenname: Mario surname: Sznol fullname: Sznol, Mario organization: Yale School of Medicine, New Haven, Connecticut – sequence: 17 givenname: Deepali surname: Rishipathak fullname: Rishipathak, Deepali organization: Genentech, Inc., South San Francisco, California – sequence: 18 givenname: Shang-Chiung surname: Chen fullname: Chen, Shang-Chiung organization: Genentech, Inc., South San Francisco, California – sequence: 19 givenname: Eric orcidid: 0000-0002-9907-2754 surname: Stefanich fullname: Stefanich, Eric organization: Genentech, Inc., South San Francisco, California – sequence: 20 givenname: Tony surname: Pourmohamad fullname: Pourmohamad, Tony organization: Genentech, Inc., South San Francisco, California – sequence: 21 givenname: Maria surname: Anderson fullname: Anderson, Maria organization: Genentech, Inc., South San Francisco, California – sequence: 22 givenname: Jeong surname: Kim fullname: Kim, Jeong organization: Genentech, Inc., South San Francisco, California – sequence: 23 givenname: Mahrukh surname: Huseni fullname: Huseni, Mahrukh organization: Genentech, Inc., South San Francisco, California – sequence: 24 givenname: Ina surname: Rhee fullname: Rhee, Ina organization: Genentech, Inc., South San Francisco, California – sequence: 25 givenname: Lillian L orcidid: 0000-0002-3500-0540 surname: Siu fullname: Siu, Lillian L organization: Princess Margaret Cancer Centre, University Health Network, Toronto, Ontario, Canada
BackLink	https://www.ncbi.nlm.nih.gov/pubmed/35699599$$D View this record in MEDLINE/PubMed
BookMark	eNpN0M1PwjAABfDGYORD_wRNj16KbdeP9UiICAkGA5hwm93aSc3W4dpp-O8lERNP7x1-eYc3BD3feAvALcFjQnj6QLBMEWYJHU-na0QJYpjiCzAgnEuUUMF7_3ofDEP4wJgwgtkV6CdcKMWVGoC3mWtDRAuP5l2tPXzZ62DhAm5iZ46wKWHcW7jaMQwn7413IcLn1W6NFRHQnbSOzvoY4LeLezgxX9oX1sBNUzkDt13dtOEaXJa6CvbmnCPwOnvcTudouXpaTCdLVDBCImKC5VgSxqVgVmAmUprniiiFlaGpSWiOFZdMcFNSZhhjJZZWF8IKYzTOJR2B-9_dQ9t8djbErHahsFWlvW26kFEhBeecSH6id2fa5bU12aF1tW6P2d8r9AeBT2Nu
CitedBy_id	crossref_primary_10_1371_journal_pone_0303643 crossref_primary_10_1038_s41573_024_01053_9 crossref_primary_10_1080_14712598_2023_2249396 crossref_primary_10_1080_14796694_2024_2357063 crossref_primary_10_1186_s13046_023_02897_6 crossref_primary_10_1093_oncolo_oyaf115 crossref_primary_10_3390_biom12091209 crossref_primary_10_1016_j_isci_2025_112270 crossref_primary_10_1097_SLA_0000000000006443 crossref_primary_10_3389_fimmu_2023_1085476 crossref_primary_10_3389_fimmu_2025_1644391 crossref_primary_10_1007_s10555_024_10184_9 crossref_primary_10_3390_pharmaceutics16111461 crossref_primary_10_1002_eji_202350915 crossref_primary_10_1158_1078_0432_CCR_22_2241 crossref_primary_10_1016_j_phrs_2023_106914 crossref_primary_10_1038_s41392_024_01826_z crossref_primary_10_1186_s13045_024_01634_6 crossref_primary_10_1136_jitc_2025_011524 crossref_primary_10_1016_j_omtn_2023_07_026 crossref_primary_10_1136_jitc_2022_005301 crossref_primary_10_1158_1078_0432_CCR_23_1014 crossref_primary_10_1158_1078_0432_CCR_24_2770 crossref_primary_10_1016_j_cell_2023_03_007 crossref_primary_10_1186_s12943_024_02179_5 crossref_primary_10_1016_j_hoc_2023_05_023 crossref_primary_10_3390_cancers16173063 crossref_primary_10_1136_jitc_2023_008677 crossref_primary_10_1007_s10637_025_01518_7 crossref_primary_10_1080_15384047_2024_2426305 crossref_primary_10_1002_adhm_202401635 crossref_primary_10_1007_s12672_025_02666_1 crossref_primary_10_1038_s41577_023_00973_8 crossref_primary_10_2217_fon_2023_0962 crossref_primary_10_1186_s40364_025_00748_4
ContentType	Journal Article
Copyright	2022 The Authors; Published by the American Association for Cancer Research.
Copyright_xml	– notice: 2022 The Authors; Published by the American Association for Cancer Research.
DBID	CGR CUY CVF ECM EIF NPM 7X8
DOI	10.1158/1078-0432.CCR-21-4020
DatabaseName	Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic
DatabaseTitle	MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic
DatabaseTitleList	MEDLINE - Academic MEDLINE
Database_xml	– sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database
DeliveryMethod	no_fulltext_linktorsrc
Discipline	Medicine
EISSN	1557-3265
ExternalDocumentID	35699599
Genre	Research Support, Non-U.S. Gov't Journal Article Clinical Trial, Phase I
GrantInformation_xml	– fundername: NCI NIH HHS grantid: P30 CA008748 – fundername: NCATS NIH HHS grantid: UL1 TR001863
GroupedDBID	--- 18M 29B 2FS 2WC 34G 39C 53G 5GY 5RE 5VS 6J9 AAFWJ AAJMC ABOCM ACGFO ACIWK ACPRK ADBBV ADCOW ADNWM AENEX AFHIN AFOSN AFRAH AFUMD ALMA_UNASSIGNED_HOLDINGS BAWUL BR6 BTFSW CGR CS3 CUY CVF DIK DU5 E3Z EBS ECM EIF EJD F5P FRP GX1 IH2 KQ8 L7B LSO NPM OK1 P0W P2P QTD RCR RHI RNS SJN TR2 W2D W8F WOQ YKV 7X8
ID	FETCH-LOGICAL-c411t-464b07145764e604682bb919909d28d32b0957465df24d444f07eac6e6dda0b72
IEDL.DBID	7X8
ISICitedReferencesCount	31
ISICitedReferencesURI	http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000844076300001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN	1557-3265
IngestDate	Fri Sep 05 06:07:19 EDT 2025 Mon Jul 21 06:04:02 EDT 2025
IsDoiOpenAccess	false
IsOpenAccess	true
IsPeerReviewed	true
IsScholarly	true
Issue	16
Language	English
License	2022 The Authors; Published by the American Association for Cancer Research.
LinkModel	DirectLink
MergedId	FETCHMERGED-LOGICAL-c411t-464b07145764e604682bb919909d28d32b0957465df24d444f07eac6e6dda0b72
Notes	ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23
ORCID	0000-0001-9522-1997 0000-0003-3806-3691 0000-0002-3500-0540 0000-0002-9907-2754 0000-0002-7679-9504 0000-0001-8908-6071 0000-0001-7412-9163 0000-0002-7237-017X 0000-0002-9366-8602 0000-0001-6000-4597 0000-0001-9321-702X 0000-0002-1165-9041
OpenAccessLink	https://aacrjournals.org/clincancerres/article-pdf/28/16/3452/3185431/3452.pdf
PMID	35699599
PQID	2676555175
PQPubID	23479
ParticipantIDs	proquest_miscellaneous_2676555175 pubmed_primary_35699599
PublicationCentury	2000
PublicationDate	2022-08-15
PublicationDateYYYYMMDD	2022-08-15
PublicationDate_xml	– month: 08 year: 2022 text: 2022-08-15 day: 15
PublicationDecade	2020
PublicationPlace	United States
PublicationPlace_xml	– name: United States
PublicationTitle	Clinical cancer research
PublicationTitleAlternate	Clin Cancer Res
PublicationYear	2022
SSID	ssj0014104
Score	2.5695238
Snippet	OX40, a receptor transiently expressed by T cells upon antigen recognition, is associated with costimulation of effector T cells and impairment of regulatory...
SourceID	proquest pubmed
SourceType	Aggregation Database Index Database
StartPage	3452
SubjectTerms	Antibodies, Monoclonal, Humanized B7-H1 Antigen Carcinoma, Transitional Cell - drug therapy Humans Lung Neoplasms - drug therapy Neoplasms - pathology Urinary Bladder Neoplasms
Title	First-In-Human Phase I Study of the OX40 Agonist MOXR0916 in Patients with Advanced Solid Tumors
URI	https://www.ncbi.nlm.nih.gov/pubmed/35699599 https://www.proquest.com/docview/2676555175
Volume	28
WOSCitedRecordID	wos000844076300001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText
inHoldings	1
isFullTextHit
isPrint
link	http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1LS8NAEF7Uinjx_agvVvC62mwmu8lJSrFYsA9qhdxikt1oQJPatIL_3tkkxZMgeMkpgbA7O983MzvfEHKFDDxKMOxiCP6cQRgLFmoVMUPeuYwjW-tSZ_ZBDgau73ujOuFW1Ncqlz6xdNQqj02O_IYLKRyEd-ncTj-YmRplqqv1CI1V0rCRyhirlv5PFQGscnwgQiYeJC6cuoPHclx0FkZZFmx-3emMGa_iqN9ZZok23e3__ucO2ap5Jm1XhrFLVnS2Rzb6dSV9nzx3U-R9rJexMo1PR68IZ7RHzb3CL5onFIkhHfrQou2X3Kjr0v7QHyPsC5ri25Uaa0FNGpe263sE9DF_SxWdLN7zWXFAnrp3k849q6ctsBgsa84Ad810M2EAAlpg2OzyKPIsRCtPcVfZPEI2JkE4KuGgACBpSfTaQgulwlYk-SFZy_JMHxMKltsSIQ_txPUApDLFWnAjUyNFvgC8SS6XaxegNZsSRZjpfFEEP6vXJEfVBgTTSnYjsB1hxNG8kz98fUo2uelTMNq1zhlpJHiW9TlZjz_naTG7KM0En4NR_xsu08Eu
linkProvider	ProQuest
openUrl	ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=First-In-Human+Phase+I+Study+of+the+OX40+Agonist+MOXR0916+in+Patients+with+Advanced+Solid+Tumors&rft.jtitle=Clinical+cancer+research&rft.au=Kim%2C+Tae+Won&rft.au=Burris%2C+Howard+A&rft.au=de+Miguel+Luken%2C+Maria+J&rft.au=Pishvaian%2C+Michael+J&rft.date=2022-08-15&rft.issn=1557-3265&rft.eissn=1557-3265&rft.volume=28&rft.issue=16&rft.spage=3452&rft_id=info:doi/10.1158%2F1078-0432.CCR-21-4020&rft.externalDBID=NO_FULL_TEXT
thumbnail_l	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1557-3265&client=summon
thumbnail_m	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1557-3265&client=summon
thumbnail_s	http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1557-3265&client=summon